JBJoel N. Blankson

Joel N. Blankson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joel N. Blankson has a total of 417 co-authors. Here are the top co-authors by number of shared publications:

  • Robert F. Siliciano

    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

    16 shared publications
  • Justin R. Bailey

    Department of Medicine and

    12 shared publications
  • Thomas M. Williams

    Department of Pathology, University of New Mexico School of Medicine, Albuquerque, New Mexico, USA

    10 shared publications
  • Caroline C. Garliss

    Department of Medicine, Johns Hopkins Medicine

    9 shared publications
  • Maria Salgado

    Department of Medicine, Center for AIDS Research, Johns Hopkins University School of Medicine, Baltimore, Maryland Institute IrsiCaixa, Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain

    8 shared publications
  • Andrea L. Cox

    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

    7 shared publications

Latest Publications

  • Open Access

    5′ leader defects drive persistent HIV-1 viremia on long-term ART

    by Julia R. Box, Angelica Camilo-Contreras, Filippo Dragoni, Feng Yun Yue, Vitaliy Matveev, Jackson Foley, Jianwei Zhang, Yan Wei Mok, Marlene DeSousa, Jun Lai, et al.

    Traces of HIV-1 RNA can persist in plasma despite long-term suppressive antiretroviral therapy (ART). Some individuals develop nonsuppressible viremia (NSV), characterized by detectable HIV-1 RNA that raises concerns for virological failure, pathogenesis, and transmission. The sources of NSV remain poorly defined, in part due to limited tools to characterize plasma HIV-1 RNA. Both infectious and defective proviruses, including those with defects in the 5′ Leader (5′L), can contribute to NSV, but their relative contributions have not been quantified. Here we show that in over 50 participants, plasma viremia is markedly driven by highly clonal HIV-1 RNA populations carrying defects in the 5′L. Across individuals, dominant clones with 5′L defects clustered around the major splice donor (MSD) accounted for the vast majority of circulating HIV-1 RNA. To enable rapid, scalable profiling, we developed CLAWS (Capturing 5′ Leader Anomalies Without Sequencing), a digital PCR assay that distinguishes intact from defective 5′L RNA. CLAWS recapitulated sequencing-based estimates and detected low-abundance defective RNA early after ART initiation, revealing that defective genomes emerge early and become predominant during long-term therapy. These findings identify 5′L-defective genomes as the predominant driver of NSV and establish CLAWS as a practical tool for monitoring viremia in clinical and cure-related settings.


  • What can spontaneous controllers, posttreatment controllers and postintervention controllers teach us about an HIV cure?

    by Joel N. Blankson

    Purpose of review: HIV controllers are a heterogenous population of people living with HIV who control viral replication without antiretroviral therapy. The purpose of this review is to summarize potential mechanisms of control and to highlight how these can be used in HIV cure strategies. Recent findings: Several recent studies have identified potent HIV-specific CD8 + T cell responses in posttreatment controllers who controlled viral replication after the discontinuation of antiretroviral therapy and postintervention controllers who achieved control after receiving broadly neutralizing antibodies alone or in conjunction with other immune modulators before antiretroviral therapy was discontinued. Other studies have implicated autologous neutralizing antibodies as a correlate of protection in both groups of controllers. Summary: The early initiation of antiretroviral therapy coupled with strategies to enhance HIV-specific CD8 + T cell and autologous neutralizing antibodies may lead to a higher incidence of posttreatment control.


  • Open Access

    T cell immunity to seasonal Influenza A and H5N1 viruses in laboratory workers receiving annual seasonal Influenza vaccines

    by Joel Sop, Tyler P. Beckey, Lizeth Gutierrez, Li Zhang, Kelly A. Gebo, Kellie N. Smith, Joel N. Blankson

    Background: Emerging threats such as highly pathogenic influenza strains like H5N1 emphasize the need for vaccines that induce cross-reactive immunity against conserved epitopes. Existing influenza vaccines primarily elicit strain-specific responses, leaving gaps in protection against pandemic subtypes. This study aimed to evaluate T cell responses to seasonal influenza A and H5N1 and compare them to SARS-CoV-2 specific T cell responses to understand differences shaped by distinct exposure histories and vaccination strategies. Methods: T cell responses were assessed in 41 laboratory workers who received annual seasonal influenza vaccines using ELISpot to quantify responses to peptide pools derived from influenza (H1N1 hemagglutinin [HA], H3N2 HA, H5N1 HA, matrix protein 1 [MP1], nucleoprotein [NP]) and SARS-CoV-2 (spike [S2S], nucleocapsid [S2N]). Ten-day expansion assays were used to evaluate functional cross-reactivity between H1, H3, and H5 HA. Intracellular cytokine staining was performed to assess antigen-specific T cell functionality. We used the IFN-γ ELISpot assay and intracellular cytokine staining to evaluate T cell responses to H5N1 HA peptides and assessed cross-reactivity and functional similarity in H1N1 HA-expanded cells. Results: The percentage of individuals with effector T cell responses to influenza peptide pools, was markedly lower than the percentage of individuals with S2S-specific T cells. However, HA-specific memory cells that cross-recognized H1, H3, and H5 HA were present in many individuals. T cells expanded with H1 or H5 HA proteins cross-recognized homologous epitopes in the 2 proteins and cytokine production profiles were comparable between H1- and H5-expanded T cells. Conclusion: These results highlight the potential for influenza vaccines to elicit cross-reactive immunity against H5N1 viruses. These findings also demonstrate differences between T cell responses to influenza and SARS-CoV-2, highlighting distinct immune profiles that could inform future vaccine strategies.


  • Open Access

    Selective targeting of HIV-infected clones by cognate peptide stimulation and antiproliferative drugs

    by Filippo Dragoni, Joel Sop, Isha Gurumurthy, Tyler P. Beckey, Kellie N. Smith, Francesco R. Simonetti, Joel N. Blankson

    Clonal expansion of HIV-infected CD4 + T cells is a barrier to HIV eradication. We previously described a marked reduction in the frequency of the most clonally expanded, infected CD4 + T cells in an individual with elite control (ES24) after initiating chemoradiation for metastatic lung cancer with a regimen that included paclitaxel and carboplatin. We tested the hypothesis that this phenomenon was due to a higher susceptibility to the chemotherapeutic drugs of CD4 + T cell clones that were sustained by proliferation. We studied a CD4 + T cell clone with replication-competent provirus integrated into the ZNF721 gene, termed ZNF721i. We stimulated the clone with its cognate peptide and then exposed the cells to paclitaxel and/or carboplatin or the antiproliferative drug mycophenolate mofetil. While treatment of cells with the cognate peptide alone led to a marked expansion of the ZNF721i clone, treatment with the cognate peptide followed by culture with either paclitaxel or mycophenolate mofetil abrogated this process. The drugs did not affect the proliferation of other CD4 + T cell clones that were not specific for the cognate peptide. This strategy of antigen-specific stimulation followed by treatment with an antiproliferative agent may lead to the selective elimination of clonally expanded HIV-infected cells.


  • Open Access

    SARS-CoV-2 vaccines induce a diverse spike-specific CD4+ T cell receptor repertoire in people living with HIV with low CD4 nadirs

    by Alicia Mercado, Joel Sop, Steven Amanat, Li Zhang, Natasha M. Chida, Christie R. Basseth, Kelly A. Gebo, Annukka A. R. Antar, Kellie N. Smith, Zhen Zeng, et al.

    People living with HIV with low CD4 T cell nadirs on antiretroviral therapy have suboptimal responses to immunization. We analyzed the SARS-CoV-2 spike-specific CD4+ T cell repertoire in individuals with CD4 nadirs of less than 100 cells/ul who received a primary SARS-CoV-2 mRNA vaccine series as well as the bivalent ancestral/BA.5 spike mRNA vaccine. We tested the hypothesis that antigenic imprinting would result in the preferential expansion of pre-existing cross-reactive T cells that were primed against the 4 common cold coronaviruses. We found that these individuals made robust effector and memory T cell responses to the SARS-CoV-2 spike protein that exceeded the responses to spike proteins from the common cold coronaviruses. Furthermore, in 4 individuals, the number of SARS-CoV-2 specific TCRs far exceeded the number of common cold coronavirus-specific T cell receptors. TCRs that were cross-reactive for common cold coronaviruses and SARS-CoV-2 comprised less than 10% of the total detected SARS-CoV-2 specific T cells. The diversity of the SARS-CoV-2 spike-specific repertoire in 6 study participants was comparable to that of the repertoire in vaccinated HIV healthy donors. Our data suggests people living with HIV with low CD4 nadirs can have significant functional immune reconstitution with little evidence of antigenic imprinting due to pre-existing T cell responses to common cold coronaviruses.


  • Open Access

    CD4+ T cell recognition of HIV-1 alternate reading frame proteins

    by Joel Sop, Tyler P. Beckey, Joel N. Blankson

    HIV-1 alternative reading frame proteins (ARFPs) have been shown to elicit CD8+ T cell responses, but less is known about the recognition of these proteins by CD4+ T cells. In this study, we analyzed responses of CD8-depleted peripheral blood mononuclear cells from chronic progressors (CPs) on suppressive antiretroviral therapy to ARFP peptide pools derived from HIV Gag, polymerase (Pol), and envelope (Env) proteins. Memory CD4+ T cell responses were detected to Gag ARFP peptide pools in 7 out of 13 CPs and to Env ARFP peptide pools in 2 out of 13 CPs. Individual peptide stimulation identified immunogenic peptides that were predicted to bind to major histocompatibility complex class II (MHC-II) proteins. HIV RNA was detected in culture supernatants from 3 of 6 CPs following stimulation of CD4+ T cells with ARFP peptide pools. These findings demonstrate that ARFP-derived peptides elicit antigen-specific CD4+ T cell responses and may contribute to latency reversal. Our data expand the known HIV immunopeptidome and suggest that ARFPs may serve as potential targets for immune-based interventions.

  • Open Access

    The XBB.1.5 mRNA booster vaccine does not significantly increase the percentage of XBB.1.5 mono-reactive T cells

    by Joel Sop, Alicia Mercado, Alexis Figueroa, Tyler P. Beckey, Caroline C. Traut, Li Zhang, Kellie N. Smith, Joel N. Blankson

    Recent efforts in vaccine development have targeted spike proteins from evolving SARS-CoV-2 variants. In this study, we analyzed T cell responses to the XBB.1.5 and BA.2.86 subvariants in individuals who previously received bivalent vaccines containing mRNA for ancestral and BA.5 spike proteins. T cell-mediated cytokine responses to spike proteins from both variants were largely preserved. To determine the mechanism of this preserved recognition, we utilized the functional expansion of specific T cells (FEST) assay to distinguish between the presence of T cells that cross-recognized ancestral and variant epitopes versus distinct populations of T cells that were mono-reactive for ancestral or variant epitopes. We found the majority of spike-specific T cells cross-recognized the ancestral spike and the XBB.1.5 and BA.2.86 subvariants, with less than 10% of T cells being mono-reactive for either variant. Interestingly, immunization with the XBB.1.5 monovalent booster vaccine did not significantly increase the percentage of XBB.1.5 mono-reactive T cells. Our results suggest a potential limitation in the induction of mono-reactive T cell responses by variant-specific booster vaccines.


  • Open Access

    Sustained orthopoxvirus-specific T-cell responses in individuals who have recovered from mpox

    by Joel Sop, Tyler P Beckey, Joyce L Jones, Bhakti Hansoti, Kelly A Gebo, Joel N Blankson


  • Open Access

    Immune Responses in Controllers of HIV Infection

    by Abena K. Kwaa, Joel N. Blankson

    Elite controllers are a heterogeneous group of people living with HIV who control viral replication without antiretroviral therapy. There is substantial evidence that at least some elite controllers are infected with replication-competent virus, thus they may serve as a model of a functional cure of HIV. The mechanisms responsible for virologic control have been actively studied. The most objective data support CD8+ T cell–based mechanisms of control, but other immune responses, mediated by antibodies and natural killer cells, may also play a role in controlling viral replication. In this article, we review the evidence for different mechanisms of immune control in these remarkable individuals.